drugset / Trial / NCT04404517

Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks

NCT04404517

Phase 3 Unknown 20 enrolled Hospital Universitario La Paz
RandomizedCrossoverOpen-labelTreatment

Summary

RCT to evaluate possible pharmacokinetic differences between the two current regimes of intensified adalimumab administration.

Timeline

Start
2019-10-01
Primary completion
2021-09-30
Completion
2021-10-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Comparator Adalimumab Monoclonal antibody 80 mg Subcutaneous